https://scholars.lib.ntu.edu.tw/handle/123456789/640201
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Kelly, William K | en_US |
dc.contributor.author | Danila, Daniel C | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | Lee, Jae-Lyun | en_US |
dc.contributor.author | Matsubara, Nobuaki | en_US |
dc.contributor.author | Ward, Patrick J | en_US |
dc.contributor.author | Armstrong, Andrew J | en_US |
dc.contributor.author | Pook, David | en_US |
dc.contributor.author | Kim, Miso | en_US |
dc.contributor.author | Dorff, Tanya B | en_US |
dc.contributor.author | Fischer, Stefanie | en_US |
dc.contributor.author | Lin, Yung-Chang | en_US |
dc.contributor.author | Horvath, Lisa G | en_US |
dc.contributor.author | Sumey, Christopher | en_US |
dc.contributor.author | Yang, Zhao | en_US |
dc.contributor.author | Jurida, Gabor | en_US |
dc.contributor.author | Smith, Kristen M | en_US |
dc.contributor.author | Connarn, Jamie N | en_US |
dc.contributor.author | Penny, Hweixian L | en_US |
dc.contributor.author | Stieglmaier, Julia | en_US |
dc.contributor.author | Appleman, Leonard J | en_US |
dc.date.accessioned | 2024-03-04T02:00:32Z | - |
dc.date.available | 2024-03-04T02:00:32Z | - |
dc.date.issued | 2024-01-12 | - |
dc.identifier.issn | 21598274 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/640201 | - |
dc.description.abstract | Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Cancer discovery | en_US |
dc.title | Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1158/2159-8290.CD-23-0964 | - |
dc.identifier.pmid | 37861461 | - |
dc.identifier.scopus | 2-s2.0-85182501012 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85182501012 | - |
dc.relation.journalvolume | 14 | en_US |
dc.relation.journalissue | 1 | en_US |
dc.relation.pageend | 89 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。